EPHA7 and neuroendocrine neoplasm: EPHA7 deep deletion is classified as a likely oncogenic/likely loss of function CNA by OncoKB and has also been identified in cutaneous melanomas, lymphomas, solid organ carcinomas (prostate, lung, and gastrointestinal tract adenocarcinomas), and neuroendocrine tumors (phaeochromocytomas and paragangliomas).